During my master’s thesis, I started working on the HIV field evaluating a new latency reversing agent called ST76AA12 (Badia, R. and Grau. J et al; Antivir Research 2015) in Institut de Recerca de la Sida IrsiCaixa. At the beginning of 2016, I started my PhD studies in Vall d’Hebron Institut de Recerca (VHIR) under the supervision of Maria José Buzón. My thesis was focused on the setup and application of a new technology able to detect both RNA and surface or intracellular proteins by flow cytometry to study the viral HIV reservoirs that persist in patients successfully treated with antiretroviral therapy (ART). As a result of my research, we characterize for the first time the presence of transcriptionally active viral reservoirs in different subpopulations of CD4 T cells both in viremic and ART-suppressed patients (Grau-Expósito et al; mBio 2017). Next, using this methodology, we studied the reactivation induced by different latency reversing agents (HDACi, PKC agonists and a bromodomain inhibitor) and its combinations in the different CD4 T cell subpopulations of patients with suppressed viral load (Grau-Expósito et al; Plos Pathogens 2019). Those investigations were significant because demonstrated that in the face of ART, exist an active viral reservoir which present differences between subpopulations. Moreover, our results validate the use of the RNA FISH/flow technique to assess the potency of LRAs among different CD4+ T cell subsets, manifest the intrinsic differences between cells that encompass the latent HIV reservoir, and highlight the difficulty to significantly impact the latent infection with the currently available drugs. Besides, I also worked on the identification of resident memory CD4 T cells from cervical tissue from women as a new HIV reservoir (Cantero J., and Grau-Expósito. J. et al; Nature Communications 2019) and on the characterization of CD32 as a marker of a transcriptionally active reservoir (Abdel-Mohsen M, Kuri-Cervantes L., and Grau-Expósito J. et al.; Sci Tans Med 2018). Moreover, in the last months, since SARS-CoV-2 emerged, I also have been focused in the generation of pseudotyped SARS-Cov-2 virus for the screening of different drugs to inhibit the entry of the SARS-Cov-2 to target cells, and on the deep characterization of peripheral and lung resident T cell responses against SARS-CoV-2 (Grau-Expósito J., and Sánchez-Gaona N, et al; MedRxiv 2020). In November 2020, I obtained my PhD awarded with the disctinction Cum Laude. Finally, at the end of 2021, I obtained the postdoctoral fellowship Juan de la Cierva - Formación and in 2022, I moved to the Institut d'Investigacion Biomèdiques August Pi i Sunyer de Barcelona (IDIBAPS) to continue my research in the HIV field.